Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.56 |
| ▸ | PRCP | P42785 | 5/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330238 | 0.98 | OPRM1 (0.57) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL329925 | 0.98 | OPRM1 (0.57) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL329828 | 0.98 | OPRM1 (0.57) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL329886 | 0.87 | OPRM1 (0.59) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL8790382 | 0.85 | OPRM1 (0.49) | OPRM1PRCPSLC22A1SMN1; SMN2KDM4E | |
| SCHEMBL9530399 | 0.85 | OPRM1 (0.54) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9423819 | 0.84 | PRCP (0.56) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9373828 | 0.82 | PRCP (0.51) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9373834 | 0.82 | PRCP (0.51) | OPRM1PRCPSLC22A1GAASMN1; SMN2 | |
| SCHEMBL9373842 | 0.82 | PRCP (0.51) | OPRM1PRCPSLC22A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102040556-B | Optical isomer of indene quinolone, preparation method and medical application thereof | YANGTZE RIVER PHARM GROUP CO | 2012-05-23 | — | — | CN | disclosed |
| CN-102040556-A | Optical isomers of indene quinazoline, preparation method and medicinal application thereof | YANGTZE RIVER PHARM GROUP CO | 2011-05-04 | — | — | CN | disclosed |
| US-7820692-B2 | Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2010-10-26 | — | — | US | disclosed |
| US-20090275607-A1 | Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2009-11-05 | — | — | US | disclosed |
| CN-100503571-C | Tetrahydro isoquinoline derivative and its preparation process and medicine use | UNIV CHINA PHARMA (CN) | 2009-06-24 | — | — | CN | disclosed |
| EP-2045243-A1 | TETRAHYDRO ISOQUINOLINE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | China Pharmaceutical University (CN) | 2009-04-08 | — | — | EP | disclosed |
| CN-1887872-A | Tetrahydro isoquinoline derivative and its prepn process and medicine use | UNIV CHINA PHARMACY (CN) | 2007-01-03 | — | — | CN | disclosed |
| EP-0569802-B1 | Arylacetamides | MERCK PATENT GMBH (DE) | 1998-07-15 | — | — | EP | disclosed |
| US-5532266-A | Acrylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5472961-A | Acetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-05 | — | — | US | disclosed |
| EP-0670318-A2 | Acetamides with analgesic and neuroprotective activity | MERCK PATENT GmbH (DE) | 1995-09-06 | — | — | EP | disclosed |
| EP-0370732-B1 | Heterocyclic compounds containing nitrogen | SMITHKLINE BEECHAM FARMA (IT) | 1994-10-12 | — | — | EP | disclosed |
| EP-0569802-A1 | Arylacetamides | MERCK PATENT GmbH (DE) | 1993-11-18 | — | — | EP | disclosed |
| EP-0232989-B1 | ISOQUINOLINE DERIVATIVES | Dr. Lo. Zambeletti S.p.A. (IT) | 1991-08-21 | — | — | EP | disclosed |
| US-5041451-A | Analgesics, hypotensive agents | DR. LO. ZAMBELLETTI SPA (IT) | 1991-08-20 | — | — | US | disclosed |
| EP-0374756-A2 | Nitrogen-containing cyclic compounds | MERCK PATENT GmbH (DE) | 1990-06-27 | — | — | EP | disclosed |
| EP-0370732-A2 | Heterocyclic compounds containing nitrogen | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1990-05-30 | — | — | EP | disclosed |
| US-4806547-A | Isoquinoline derivatives, analgesic compounds thereof and method of treating pain | DR. LO. ZAMBELETTI SPA (IT) | 1989-02-21 | — | — | US | disclosed |
| EP-0232989-A2 | Isoquinoline derivatives | Dr. Lo. Zambeletti S.p.A. (IT) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275607-A1 | Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof | OPRK1, OPRD1, OPRL1 | OPRM1 4/4885PRCP 4320/4885SLC22A1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.